Literature DB >> 12941828

Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.

Karl G Kohlgraf1, Andrew J Gawron, Michiyo Higashi, Jane L Meza, Michael D Burdick, Shinichi Kitajima, David L Kelly, Thomas C Caffrey, Michael A Hollingsworth.   

Abstract

MUC1 is a polymorphic, highly glycosylated, type I transmembrane protein expressed by ductal epithelial cells of many organs including pancreas, breast, gastrointestinal tract, and airway. MUC1 is overexpressed and differentially glycosylated by adenocarcinomas that arise in these organs, and is believed to contribute to invasive and metastatic potential by contributing to cell surface adhesion properties [via the tandem repeat (TR) domain] and through morphogenetic signal transduction [via the cytoplasmic tail (CT)]. The large extracellular TR of MUC1 consists of a heavily glycosylated, 20 amino acid sequence that shows allelic variation with respect to number of repeats. This portion of MUC1 may directly mediate adhesive or antiadhesive interactions with other surface molecules on adjacent cells and through these interactions initiate signal transduction pathways that are transmitted through the CT. We investigated the contribution of the TR domain and the CT of MUC1 to the in vivo invasive and metastatic potential, and the gene expression profile of the human pancreatic tumor cell line S2-013. Results showed that S2-013 cells overexpressing full-length MUC1 displayed a less invasive and metastatic phenotype compared with control-transfected cells and cells expressing MUC1 lacking the TR domain or CT. Clonal populations were analyzed by cDNA array gene expression analysis, which showed differences in the gene expression profiles between the different cell lines. Among the genes differentially expressed were several that encode proteins believed to play a role in invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941828

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal.

Authors:  Carol L Kinlough; Paul A Poland; Sandra J Gendler; Polly E Mattila; Di Mo; Ora A Weisz; Rebecca P Hughey
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

2.  Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Authors:  Pankaj K Singh; Michelle E Behrens; John P Eggers; Ronald L Cerny; Jennifer M Bailey; Kandavel Shanmugam; Sandra J Gendler; Eric P Bennett; Michael A Hollingsworth
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

3.  Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.

Authors:  Zuxiong Chen; Zulfiqar G Gulzar; Catherine A St Hill; Bruce Walcheck; James D Brooks
Journal:  Prostate       Date:  2014-05-22       Impact factor: 4.104

4.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

5.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Authors:  Usanarat Anurathapan; Robert C Chan; Hakeem F Hindi; Roopa Mucharla; Pradip Bajgain; Brendan C Hayes; William E Fisher; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Mol Ther       Date:  2013-11-28       Impact factor: 11.454

6.  The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.

Authors:  Stephanie Downs-Canner; Mazen Zenati; Brian A Boone; Patrick R Varley; Jennifer Steve; Melissa E Hogg; Amer Zureikat; Herbert J Zeh; Kenneth K W Lee
Journal:  J Surg Oncol       Date:  2015-07-07       Impact factor: 3.454

7.  RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.

Authors:  Sadaaki Yamazoe; Hiroaki Tanaka; Tetsuji Sawada; Ryosuke Amano; Nobuya Yamada; Masaichi Ohira; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-05-23

Review 8.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12

10.  Mucins in ovarian cancer diagnosis and therapy.

Authors:  Subhash C Chauhan; Deepak Kumar; Meena Jaggi
Journal:  J Ovarian Res       Date:  2009-12-24       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.